Tags

Type your tag names separated by a space and hit enter

Nationwide survey of extended-spectrum {beta}-lactamase-producing Enterobacteriaceae in the French community setting.
J Antimicrob Chemother 2009; 63(6):1205-14JA

Abstract

OBJECTIVES

The aim of this study was to assess the prevalence of the extended-spectrum beta-lactamase (ESBL)-producing enterobacteria (ESBLE) in the French community, during a 2006 survey.

METHODS

All enterobacteria isolated from urine samples of patients, exhibiting a decreased susceptibility to broad-spectrum cephalosporins, were analysed for their beta-lactamase content (synergy test, isoelectrofocusing, conjugation transfer, PCR amplification and/or cloning experiments and sequencing). Additional co-resistances were investigated by PCR, sequencing and/or cloning. Epidemiological relationship was studied by PFGE for all species and, in addition, for Escherichia coli by the determination of the phylogenetic group, multilocus sequence type (ST) and O25b antigen. Characteristics of CTX-M-producing E. coli carriers were compared with other ESBLE carriers.

RESULTS

Seventy-two ESBLE were collected from 71 patients. Most of them expressed a CTX-M enzyme (n = 42, comprising 40 E. coli), with a predominance of CTX-M-15 (n = 24); 10 CTX-M-15-producing E. coli belonged to the same clone (phylogroup B2, ST131, serotype O25b). The 30 remaining strains possessed a TEM- or SHV-type ESBL. In addition, three strains presented unusual co-resistances such as DHA-1 (n = 2), QnrB4 and ArmA. Risk factors for ESBLE acquisition were substantially less frequent when the ESBL was of the CTX-M type, except for prior antimicrobial therapy. Eighteen percent of the patients were considered to have true community-acquired ESBLE; most of them harboured a CTX-M-producing E. coli.

CONCLUSIONS

This first nationwide study reports an ESBLE prevalence of 1.1% in the French community setting in 2006, mainly related to the presence of CTX-M-producing E. coli strains; furthermore, unusual co-resistances rarely found in the community setting were occasionally observed, which may threaten future emergence.

Authors+Show Affiliations

CNRS UMR, Université Bordeaux, France. corinne.arpin@bacterio.u-bordeaux2.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19329798

Citation

Arpin, C, et al. "Nationwide Survey of Extended-spectrum {beta}-lactamase-producing Enterobacteriaceae in the French Community Setting." The Journal of Antimicrobial Chemotherapy, vol. 63, no. 6, 2009, pp. 1205-14.
Arpin C, Quentin C, Grobost F, et al. Nationwide survey of extended-spectrum {beta}-lactamase-producing Enterobacteriaceae in the French community setting. J Antimicrob Chemother. 2009;63(6):1205-14.
Arpin, C., Quentin, C., Grobost, F., Cambau, E., Robert, J., Dubois, V., ... André, C. (2009). Nationwide survey of extended-spectrum {beta}-lactamase-producing Enterobacteriaceae in the French community setting. The Journal of Antimicrobial Chemotherapy, 63(6), pp. 1205-14. doi:10.1093/jac/dkp108.
Arpin C, et al. Nationwide Survey of Extended-spectrum {beta}-lactamase-producing Enterobacteriaceae in the French Community Setting. J Antimicrob Chemother. 2009;63(6):1205-14. PubMed PMID: 19329798.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Nationwide survey of extended-spectrum {beta}-lactamase-producing Enterobacteriaceae in the French community setting. AU - Arpin,C, AU - Quentin,C, AU - Grobost,F, AU - Cambau,E, AU - Robert,J, AU - Dubois,V, AU - Coulange,L, AU - André,C, AU - ,, Y1 - 2009/03/28/ PY - 2009/3/31/entrez PY - 2009/3/31/pubmed PY - 2009/7/1/medline SP - 1205 EP - 14 JF - The Journal of antimicrobial chemotherapy JO - J. Antimicrob. Chemother. VL - 63 IS - 6 N2 - OBJECTIVES: The aim of this study was to assess the prevalence of the extended-spectrum beta-lactamase (ESBL)-producing enterobacteria (ESBLE) in the French community, during a 2006 survey. METHODS: All enterobacteria isolated from urine samples of patients, exhibiting a decreased susceptibility to broad-spectrum cephalosporins, were analysed for their beta-lactamase content (synergy test, isoelectrofocusing, conjugation transfer, PCR amplification and/or cloning experiments and sequencing). Additional co-resistances were investigated by PCR, sequencing and/or cloning. Epidemiological relationship was studied by PFGE for all species and, in addition, for Escherichia coli by the determination of the phylogenetic group, multilocus sequence type (ST) and O25b antigen. Characteristics of CTX-M-producing E. coli carriers were compared with other ESBLE carriers. RESULTS: Seventy-two ESBLE were collected from 71 patients. Most of them expressed a CTX-M enzyme (n = 42, comprising 40 E. coli), with a predominance of CTX-M-15 (n = 24); 10 CTX-M-15-producing E. coli belonged to the same clone (phylogroup B2, ST131, serotype O25b). The 30 remaining strains possessed a TEM- or SHV-type ESBL. In addition, three strains presented unusual co-resistances such as DHA-1 (n = 2), QnrB4 and ArmA. Risk factors for ESBLE acquisition were substantially less frequent when the ESBL was of the CTX-M type, except for prior antimicrobial therapy. Eighteen percent of the patients were considered to have true community-acquired ESBLE; most of them harboured a CTX-M-producing E. coli. CONCLUSIONS: This first nationwide study reports an ESBLE prevalence of 1.1% in the French community setting in 2006, mainly related to the presence of CTX-M-producing E. coli strains; furthermore, unusual co-resistances rarely found in the community setting were occasionally observed, which may threaten future emergence. SN - 1460-2091 UR - https://www.unboundmedicine.com/medline/citation/19329798/Nationwide_survey_of_extended_spectrum_{beta}_lactamase_producing_Enterobacteriaceae_in_the_French_community_setting_ L2 - https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dkp108 DB - PRIME DP - Unbound Medicine ER -